Experimental eye drug targets genetic blindness
NCT ID NCT05392179
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested an experimental drug called ADX-2191 in 8 adults with retinitis pigmentosa caused by specific genetic mutations. Participants received monthly injections into one eye for up to six months. The main goal was to check safety, but researchers also looked at whether the drug could help preserve vision. Because the study is very small and early-stage, it is too soon to know if the treatment will be effective for a broader group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADX-2191 (a drug injected into the eye monthly)
What this could lead to
If it works, this could point toward a treatment to slow vision loss in people with certain genetic forms of retinitis pigmentosa.
What could go wrong
This is a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Eye Center
Durham, North Carolina, 27710, United States